Growth Metrics

Acadia Pharmaceuticals (ACAD) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Consolidated Net Income rose 119.14% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.33%. This contributed to the annual value of $226.5 million for FY2024, which is 469.20% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Consolidated Net Income stood at $71.8 million for Q3 2025, which was up 169.26% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Consolidated Net Income registered a high of $143.8 million during Q4 2024, and its lowest value of -$113.1 million during Q1 2022.
  • In the last 3 years, Acadia Pharmaceuticals' Consolidated Net Income had a median value of $26.7 million in 2025 and averaged $25.7 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first slumped by 139.49% in 2023, then surged by 2,898.20% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Consolidated Net Income stood at -$43.1 million in 2021, then climbed by 3.29% to -$41.7 million in 2022, then skyrocketed by 209.77% to $45.7 million in 2023, then surged by 214.23% to $143.8 million in 2024, then skyrocketed by 119.14% to $71.8 million in 2025.
  • Its Consolidated Net Income stands at $71.8 million for Q3 2025, versus $26.7 million for Q2 2025 and $19.0 million for Q1 2025.